Abstract:Key PointsAsthma and chronic obstructive pulmonary disease (COPD) are both associated with chronic inflammation of the respiratory tract and with increased inflammation during disease exacerbations. However, the inflammatory pattern differs between these two diseases.The inflammation in asthma mainly involves the proximal airways, whereas in COPD inflammation mainly occurs in the peripheral airways and the lung parenchyma.Asthma is typically characterized by activated mucosal mast cells, an infiltration of eosinophils and activated T helper 2 (TH2) cells, whereas in COPD macrophages, neutrophils and type 1 cytotoxic T (TC1) cells predominate.These distinct patterns reflect differences in the mechanisms that drive the inflammatory response, with responses being driven by allergens in asthma and by chronic inhaled irritants, such as cigarette smoke, in COPD.The pattern of inflammatory mediators produced also differs between the two diseases. In asthma, there are increased levels of mediators, such as histamine and cysteinyl leukotrienes, that cause bronchoconstriction and of TH2-type cytokines (such as interleukin-4 (IL-4), IL-5, IL-9 and IL-13), which orchestrate the inflammatory response through activation of the transcription factors GATA3 (GATA-binding protein 3) and NFAT (nuclear factor of activated T cells). By contrast, in COPD, there is an increase in the levels of nonspecific cytokines, such as IL-6 and tumour-necrosis factor, and chemokines that are associated with monocytic and neutrophilic inflammation (such as CXCL8, CXCL1 and CCL2).In severe asthma and asthmatics who smoke, the inflammatory pattern changes to become more similar to that seen in COPD, with more involvement of the peripheral airways, increased infiltration of neutrophils and CD8+ T cells.Differences in inflammatory patterns affect the response of these two diseases to therapy. Mild asthma is very responsive to corticosteroids, as these drugs suppress the multiple inflammatory genes that are activated through recruitment of the enzyme histone deacetylase 2 (HDAC2). However, in COPD and severe asthma, corticosteroids fail to suppress inflammation owing to a reduction in HDAC2 activity and expression. In the future, specific immunosuppressants may be a useful approach to therapy.

Immunology of asthma and chronic obstructive pulmonary disease